Articles

Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) Regimen for Transplant-Ineligible Patients with Newly Diagnosed MM
ASH 2015 – Multiple Myeloma
Modification of the current treatment regimen of RVD to “RVD-lite” provided better tolerability and enhanced clinical benefits in transplant-ineligible patients and proved to be particularly manageable in older populations, even with a wide variety of performance statuses at the beginning of the study. Read More ›
Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)
ASH 2015 – Multiple Myeloma
Researchers presented 2-year follow-up safety and efficacy results of a phase 2 open-label study that compared the efficacy and safety of combination therapy with the anti-SLAM7 monoclonal antibody elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›
All-Oral Combination of Ixazomib/Cyclophosphamide/Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed MM
ASH 2015 – Multiple Myeloma
Researchers report the results of a phase 2 study evaluating the tolerability and long-term outcomes using a combination of ixazomib plus cyclophosphamide and low-dose dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not eligible for transplant. Read More ›
Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial of Bortezomib Induction and Maintenance in Patients with Newly Diagnosed MM
ASH 2015 – Multiple Myeloma
Researchers report the significant and lasting improvement in progression-free survival and overall survival in patients treated with bortezomib. A subgroup analysis identified bortezomib to have an effect on the high-risk effects of del(17p) and renal impairment on survival. Read More ›

Page 120 of 143


© Amplity, Inc. All Rights Reserved. Privacy Policy